LY2606368

Data Sheet For research use only. Not for human use.

Cat. No. ：BCP14380CAS No. ：1234015-52-1Purity：98%

Get Quotation Now

Tel: 0086-13026320035 or orders@biochempartner.com

* Required Fields.

Please complete the form below and you will get the price list in 1 minute.

* Required Fields.

Please complete the form below and we will contact you shortly.

* Required Fields.

Please complete the form below and we will contact you shortly.

CAS No.	1234015-52-1	Cat. No.	BCP14380
Related Products	1234015-55-4（Prexasertib mesylate ） 1234015-54-3（ Prexasertib dihydrochloride） 1234015-57-6（Prexasertib Mesylate Hydrate） 1234015-58-7（Prexasertib dimesylate）
Name	LY2606368
Synonyms	LY 2606368;LY-2606368; Prexasertib;
SMILES
Chemical Name
Formula	C18H19N7O2	M. Wt	365.38
Purity	98%	Storage	Store at 4-8°C
Description	LY2606368 alone significantly inhibited the cell proliferation in a variety of pancreatic cell lines (SW1990, SU86.86, Bx-PC3, AsPC-1, CFPAC-1, Capan-2, HPAF-II) with SW1990 being the most sensitive (IC50=1.5 nM). LY2606368 has been reported to inhibit Chk1 auto-phosphorylation activated by DNA damaging agents, and induce phosphorylation of H2AX, a DNA damage maker in multiple cancer cell lines in vitro. In addition, LY2606368 has demonstrated potent single agent activity and potentiates the anti-tumor activity of DNA damaging agents in vivo. Pancreatic cancer is one of the least curable cancers, with an approximate 5% overall 5-year survival for all patients. In SW1990 pancreas orthotopic model, which represents the local and metastatic growth pattern seen in pancreas cancer patients, LY2606368 treatment resulted in over 92% inhibition of primary tumor growth as well as 100% inhibition of metastasis to lymph node, spleen and intestine. The anti-tumor effect of LY2606368 treatment was